{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T07:23:48Z","timestamp":1775892228915,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T00:00:00Z","timestamp":1658966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T00:00:00Z","timestamp":1658966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006254","name":"Ruhr-Universit\u00e4t Bochum","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006254","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:sec>\n                <jats:title>Hintergrund<\/jats:title>\n                <jats:p>Die multimodale rheumatologische Komplexbehandlung (MRKB) beruht auf einem akutstation\u00e4ren Versorgungskonzept zur Behandlung von Patienten mit klinisch relevanten Funktionseinschr\u00e4nkungen und Schmerzexazerbationen, die durch rheumatische und muskuloskeletale Erkrankungen bedingt sind. Patienten mit axialer Spondyloarthritis (axSpA) einschlie\u00dflich der ankylosierenden Spondylitis (AS) leiden h\u00e4ufig unter solchen Gesundheitsproblemen. Regelm\u00e4\u00dfige Bewegungs\u00fcbungen und physikalische Therapiema\u00dfnahmen sind ein wichtiger Pfeiler im Behandlungsmanagement. Mit dem ASAS Health Index (ASAS\u00a0HI) k\u00f6nnen die globale Funktionsf\u00e4higkeit und Gesundheit von axSpA-Patienten erfasst werden. Die Trennsch\u00e4rfe des ASAS HI f\u00fcr nichtpharmakologische Therapie\u00e4nderungen ist bisher noch nicht nachgewiesen worden.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Zielsetzung<\/jats:title>\n                <jats:p>Evaluation der im Rheumazentrum Ruhrgebiet durchgef\u00fchrten MRKB und des ASAS HI f\u00fcr nichtpharmakologische Therapiema\u00dfnahmen bei Patienten mit axSpA. Als prim\u00e4rer Endpunkt wurde eine Verbesserung des ASDAS\u202f\u2265\u20091,1 festgelegt. Hierbei wurde angenommen, dass &gt;\u202f25\u202f% der Patienten diesen Schwellenwert erreichen.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methoden<\/jats:title>\n                <jats:p>Konsekutiv eingeschlossene Patienten mit aktiver axSpA und relevanten Funktionseinschr\u00e4nkungen wurden im Rahmen einer MRKB 14\u00a0Tage station\u00e4r behandelt. Alle Patienten beantworteten am ersten (V1) und am 14.\u00a0Tag (V2) des Aufenthalts Frageb\u00f6gen zu Schmerzen (NRS), Krankheitsaktivit\u00e4t (BASDAI, ASDAS) und Funktion (BASFI, ASAS HI). Die klinische Untersuchung erfolgte mittels BASMI und eine Messung des C\u2011reaktiven Proteins (CRP) zu beiden Zeitpunkten.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Ergebnisse<\/jats:title>\n                <jats:p>Die prospektiv eingeschlossenen 66\u00a0Patienten hatten ein mittleres Alter von 47,2\u00a0Jahren (SD 14,2), eine Symptomdauer von ca.\u00a020\u00a0Jahren, 65,3\u202f% waren M\u00e4nner und 75\u202f% HLA B27+, das CRP war bei 41,3\u202f% erh\u00f6ht. Die Krankheitsaktivit\u00e4t zu V1 war erh\u00f6ht: BASDAI 5,6 (1,8), ASDAS 3,1 (0,9), w\u00e4hrend Funktionsf\u00e4higkeit und Mobilit\u00e4t vermindert waren: BASFI 3,5 (1,8), BASMI 5,6 (2,1), ASAS HI 8,4 (3,4). Im Verlauf verbesserte sich das globale Patientenurteil (NRS 0\u201310) von 6,9 (1,7) zu V1 auf 4,8 (1,8) zu V2 und der Schmerz von 6,9 (1,9) auf 4,7 (2,0) (alle <jats:italic>p<\/jats:italic>\u202f&lt;\u20090,001). Auch die Krankheitsaktivit\u00e4t nahm zu V2 ab: BASDAI 4,1 (1,9), ASDAS 2,4 (1,0), Funktion und Mobilit\u00e4t waren auch verbessert: BASFI 4,3 (2,4), BASMI 2,7 (1,6), ASAS\u00a0HI 6,5 (3,8) (alle <jats:italic>p<\/jats:italic>\u202f&lt;\u20090,001).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Schlussfolgerung<\/jats:title>\n                <jats:p>In dieser Studie konnte die Wirksamkeit einer 2\u2011w\u00f6chigen MRKB gem\u00e4\u00df OPS 8\u2013983,1 hinsichtlich wichtiger patientenzentrierter Outcomes (PRO) nachgewiesen und fr\u00fchere Studienergebnisse konnten best\u00e4tigt werden. In diesem Rahmen war auch der ASAS-HI ver\u00e4nderungssensitiv.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00393-022-01241-1","type":"journal-article","created":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T11:13:33Z","timestamp":1659006813000},"page":"153-159","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Wirkung der multimodalen rheumatologischen Komplexbehandlung bei Patienten mit axialer Spondyloarthritis","Effect of multimodal rheumatologic complex treatment in patients with axial spondylarthritis"],"prefix":"10.1007","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5668-4497","authenticated-orcid":false,"given":"U.","family":"Kiltz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Wiatr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Kiefer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.","family":"Baraliakos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Braun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,28]]},"reference":[{"issue":"10089","key":"1241_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0140-6736(16)31591-4","volume":"390","author":"J Sieper","year":"2017","unstructured":"Sieper\u00a0J, Poddubnyy\u00a0D (2017) Axial spondyloarthritis. Lancet 390(10089):73\u201384","journal-title":"Lancet"},{"issue":"6","key":"1241_CR2","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","volume":"76","author":"D van der Heijde","year":"2017","unstructured":"van der Heijde\u00a0D, Ramiro\u00a0S, Landewe\u00a0R, Baraliakos\u00a0X, Van den Bosch\u00a0F, Sepriano\u00a0A et al (2017) 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 76(6):978\u2013991","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1241_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00393-019-0670-3","volume":"78","author":"U Kiltz","year":"2019","unstructured":"Kiltz\u00a0U, Braun\u00a0J, Becker\u00a0A, Chenot\u00a0JF et al (2019) Long version on the S3 guidelines for axial spondyloarthritis including Bechterew\u2019s disease and early forms, update 2019 : evidence-based guidelines of the German society for rheumatology (DGRh) and participating medical scientific specialist societies and other organizations. Z\u00a0Rheumatol 78(1):3\u201364","journal-title":"Z Rheumatol"},{"issue":"3","key":"1241_CR4","doi-asserted-by":"publisher","first-page":"607","DOI":"10.3899\/jrheum.150721","volume":"43","author":"FP Kroon","year":"2016","unstructured":"Kroon\u00a0FP, van der Burg\u00a0LR, Ramiro\u00a0S, Landewe\u00a0RB, Buchbinder\u00a0R, Falzon\u00a0L et\u00a0al (2016) Nonsteroidal antiinflammatory drugs for axial spondyloarthritis: a Cochrane review. J\u00a0Rheumatol 43(3):607\u2013617","journal-title":"J Rheumatol"},{"key":"1241_CR5","first-page":"CD005468","volume":"4","author":"LJ Maxwell","year":"2015","unstructured":"Maxwell\u00a0LJ, Zochling\u00a0J, Boonen\u00a0A, Singh\u00a0JA, Veras\u00a0MM, Tanjong Ghogomu\u00a0E et al (2015) TNF-alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev 4:CD5468","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"1241_CR6","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1136\/annrheumdis-2018-213585","volume":"77","author":"AK Rausch Osthoff","year":"2018","unstructured":"Rausch Osthoff\u00a0AK, Niedermann\u00a0K, Braun\u00a0J, Adams\u00a0J, Brodin\u00a0N, Dagfinrud\u00a0H et\u00a0al (2018) 2018 EULAR recommendations for physical activity in people with inflammatory arthritis and osteoarthritis. Ann Rheum Dis 77(9):1251\u20131260","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"1241_CR7","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1136\/annrheumdis-2013-203967","volume":"74","author":"U Kiltz","year":"2015","unstructured":"Kiltz\u00a0U, van der Heijde\u00a0D, Boonen\u00a0A, Cieza\u00a0A, Stucki\u00a0G, Khan\u00a0MA et\u00a0al (2015) Development of a\u00a0health index in patients with ankylosing spondylitis (ASAS HI): final result of a\u00a0global initiative based on the ICF guided by ASAS. Ann Rheum Dis 74(5):830\u2013835","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"1241_CR8","first-page":"2475","volume":"33","author":"I van Echteld","year":"2006","unstructured":"van Echteld\u00a0I, Cieza\u00a0A, Boonen\u00a0A, Stucki\u00a0G, Zochling\u00a0J, Braun\u00a0J et\u00a0al (2006) Identification of the most common problems by patients with ankylosing spondylitis using the international classification of functioning, disability and health. J\u00a0Rheumatol 33(12):2475\u20132483","journal-title":"J Rheumatol"},{"issue":"11","key":"1241_CR9","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1136\/ard.2004.027185","volume":"64","author":"T Sigl","year":"2005","unstructured":"Sigl\u00a0T, Cieza\u00a0A, van der Heijde\u00a0D, Stucki\u00a0G (2005) ICF based comparison of disease specific instruments measuring physical functional ability in ankylosing spondylitis. Ann Rheum Dis 64(11):1576\u20131581","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"1241_CR10","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1136\/annrheumdis-2017-212076","volume":"77","author":"U Kiltz","year":"2018","unstructured":"Kiltz\u00a0U, van der Heijde\u00a0D, Boonen\u00a0A, Akkoc\u00a0N, Bautista-Molano\u00a0W, Burgos-Vargas\u00a0R et al (2018) Measurement properties of the ASAS health index: results of a\u00a0global study in patients with axial and peripheral spondyloarthritis. Ann Rheum Dis 77(9):1311\u20131317","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1241_CR11","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1136\/ard.2009.108233","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit\u00a0M, van der Heijde\u00a0D, Landewe\u00a0R, Listing\u00a0J, Akkoc\u00a0N, Brandt\u00a0J et\u00a0al (2009) The development of assessment of spondyloarthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 68(6):777\u2013783","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"1241_CR12","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s00393-005-0783-8","volume":"64","author":"HJ Lakomek","year":"2005","unstructured":"Lakomek\u00a0HJ, Fiori\u00a0W, Buscham\u00a0K, Hulsemann\u00a0JL, Koneke\u00a0N, Liman\u00a0W et\u00a0al (2005) The multimodal rheumatologic complex treatment (OPS 8\u2013983)\u2014challenges, solutions and perspectives. Z\u00a0Rheumatol 64(8):557\u2013563","journal-title":"Z Rheumatol"},{"key":"1241_CR13","volume-title":"Information DIfMDu","author":"Deutsches Institut f\u00fcr Medizinische Dokumentation und Information","year":"2018","unstructured":"Deutsches Institut f\u00fcr Medizinische Dokumentation und Information (2018) Information DIfMDu. https:\/\/www.dimdi.de\/static\/de\/klassifikationen\/ops\/kode-suche\/opshtml2022\/block-8-97...8-98.htm"},{"issue":"4","key":"1241_CR14","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/art.1780270401","volume":"27","author":"S van der Linden","year":"1984","unstructured":"van der Linden\u00a0S, Valkenburg\u00a0HA, Cats\u00a0A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27(4):361\u2013368","journal-title":"Arthritis Rheum"},{"key":"1241_CR15","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1002\/acr.20671","volume":"64","author":"M Dougados","year":"2012","unstructured":"Dougados\u00a0M et\u00a0al (2012) Nonsteroidal antinflammatory drug intake according to the Assessment.... Arthritis Care Res 64:290\u2013294","journal-title":"Arthritis Care Res"},{"issue":"9","key":"1241_CR16","first-page":"1694","volume":"21","author":"TR Jenkinson","year":"1994","unstructured":"Jenkinson\u00a0TR, Mallorie\u00a0PA, Whitelock\u00a0HC, Kennedy\u00a0LG, Garrett\u00a0SL, Calin\u00a0A (1994) Defining spinal mobility in ankylosing spondylitis (AS). The bath AS metrology index. J\u00a0Rheumatol 21(9):1694\u20131698","journal-title":"J Rheumatol"},{"issue":"12","key":"1241_CR17","first-page":"2286","volume":"21","author":"S Garrett","year":"1994","unstructured":"Garrett\u00a0S, Jenkinson\u00a0T, Kennedy\u00a0LG, Whitelock\u00a0H, Gaisford\u00a0P, Calin\u00a0A (1994) A new approach to defining disease status in ankylosing spondylitis: the bath ankylosing spondylitis disease activity index. J\u00a0Rheumatol 21(12):2286\u20132291","journal-title":"J Rheumatol"},{"issue":"1","key":"1241_CR18","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1136\/ard.2008.094870","volume":"68","author":"C Lukas","year":"2009","unstructured":"Lukas\u00a0C, Landewe\u00a0R, Sieper\u00a0J, Dougados\u00a0M, Davis\u00a0J, Braun\u00a0J et al (2009) Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 68(1):18\u201324","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"1241_CR19","first-page":"2281","volume":"21","author":"A Calin","year":"1994","unstructured":"Calin\u00a0A, Garrett\u00a0S, Whitelock\u00a0H, Kennedy\u00a0LG, O\u2019Hea\u00a0J, Mallorie\u00a0P et\u00a0al (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the bath ankylosing spondylitis functional index. J\u00a0Rheumatol 21(12):2281\u20132285","journal-title":"J Rheumatol"},{"issue":"3","key":"1241_CR20","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"The EuroQol Group","year":"1990","unstructured":"The EuroQol Group (1990) EuroQol\u2014a new facility for the measurement of health-related quality of life. Health Policy 16(3):199\u2013208","journal-title":"Health Policy"},{"key":"1241_CR21","volume-title":"SF-36 health survey. Manual and interpretation guide","author":"J Ware Jr.","year":"2000","unstructured":"Ware\u00a0J Jr., Snow\u00a0KK, Kosinski\u00a0M, Gandek\u00a0B (2000) SF-36 health survey. Manual and interpretation guide. Quality Metric Inc, Lincoln, RI"},{"key":"1241_CR22","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1002\/acr.20131","volume":"62","author":"WP Maksymowych","year":"2010","unstructured":"Maksymowych\u00a0WP et\u00a0al (2010) THresholds of patient-reproted outcomes that define the patient-acceptable symptom state in ankylosing spondylitis vary over time and by treatment and patient characteristics. Arthritis Care Res 62:826\u2013834","journal-title":"Arthritis Care Res"},{"issue":"5","key":"1241_CR23","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1007\/s10067-019-04887-6","volume":"39","author":"P Klemm","year":"2020","unstructured":"Klemm\u00a0P, Hudowenz\u00a0O, Asendorf\u00a0T, Dischereit\u00a0G, Muller-Ladner\u00a0U, Lange\u00a0U et al (2020) Evaluation of a\u00a0special concept of physical therapy in spondyloarthritis: German multimodal rheumatologic complex treatment for spondyloarthritis. Clin Rheumatol 39(5):1513\u20131520","journal-title":"Clin Rheumatol"},{"key":"1241_CR24","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ejim.2021.07.005","volume":"93","author":"P Klemm","year":"2021","unstructured":"Klemm\u00a0P, Preusler\u00a0P, Hudowenz\u00a0O, Asendorf\u00a0T, Muller-Ladner\u00a0U, Neumann\u00a0E et al (2021) Multimodal rheumatologic complex treatment in patients with spondyloarthritis\u2014a\u00a0prospective study. Eur J Intern Med 93:42\u201349","journal-title":"Eur J Intern Med"},{"issue":"10","key":"1241_CR25","first-page":"2029","volume":"33","author":"E Lubrano","year":"2006","unstructured":"Lubrano\u00a0E, D\u2019Angelo\u00a0S, Parsons\u00a0WJ, Serino\u00a0F, Tanzillo\u00a0AT, Olivieri\u00a0I et\u00a0al (2006) Effects of a\u00a0combination treatment of an intensive rehabilitation program and etanercept in patients with ankylosing spondylitis: a\u00a0pilot study. J\u00a0Rheumatol 33(10):2029\u20132034","journal-title":"J Rheumatol"},{"issue":"6","key":"1241_CR26","doi-asserted-by":"publisher","first-page":"534","DOI":"10.2340\/16501977-0804","volume":"43","author":"YA Staalesen Strumse","year":"2011","unstructured":"Staalesen Strumse\u00a0YA, Nordvag\u00a0BY, Stanghelle\u00a0JK, Roisland\u00a0M, Winther\u00a0A, Pajunen\u00a0PA et al (2011) Efficacy of rehabilitation for patients with ankylosing spondylitis: comparison of a\u00a0four-week rehabilitation programme in a\u00a0Mediterranean and a\u00a0Norwegian setting. J\u00a0Rehabil Med 43(6):534\u2013542","journal-title":"J Rehabil Med"},{"issue":"7","key":"1241_CR27","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.3899\/jrheum.100987","volume":"38","author":"S Masiero","year":"2011","unstructured":"Masiero\u00a0S, Bonaldo\u00a0L, Pigatto\u00a0M, Nigro\u00a0LA, Ramonda\u00a0R, Punzi\u00a0L (2011) Rehabilitation treatment in patients with ankylosing spondylitis stabilized with tumor necrosis factor inhibitor therapy: a\u00a0randomized controlled trial. J\u00a0Rheumatol 38(7):1335\u20131342","journal-title":"J Rheumatol"},{"issue":"3","key":"1241_CR28","doi-asserted-by":"publisher","first-page":"260","DOI":"10.2340\/16501977-1078","volume":"45","author":"I Kjeken","year":"2013","unstructured":"Kjeken\u00a0I, Bo\u00a0I, Ronningen\u00a0A, Spada\u00a0C, Mowinckel\u00a0P, Hagen\u00a0KB et al (2013) A three-week multidisciplinary in-patient rehabilitation programme had positive long-term effects in patients with ankylosing spondylitis: randomized controlled trial. J\u00a0Rehabil Med 45(3):260\u2013267","journal-title":"J Rehabil Med"},{"issue":"1","key":"1241_CR29","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s00296-011-2147-9","volume":"33","author":"L Ciprian","year":"2013","unstructured":"Ciprian\u00a0L, Lo Nigro\u00a0A, Rizzo\u00a0M, Gava\u00a0A, Ramonda\u00a0R, Punzi\u00a0L et\u00a0al (2013) The effects of combined spa therapy and rehabilitation on patients with ankylosing spondylitis being treated with TNF inhibitors. Rheumatol Int 33(1):241\u2013245","journal-title":"Rheumatol Int"},{"issue":"11","key":"1241_CR30","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1136\/annrheumdis-2020-219585","volume":"80","author":"A Molto","year":"2021","unstructured":"Molto\u00a0A, Lopez-Medina\u00a0C, Van den Bosch\u00a0FE, Boonen\u00a0A, Webers\u00a0C, Dernis\u00a0E et al (2021) Efficacy of a\u00a0tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial. Ann Rheum Dis 80(11):1436\u20131444","journal-title":"Ann Rheum Dis"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-022-01241-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-022-01241-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-022-01241-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T15:06:05Z","timestamp":1709132765000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-022-01241-1"}},"subtitle":["Eine systematische Erhebung mit standardisierten Outcomeparametern wie dem ASAS-Gesundheitsindex","A systematic evaluation with standardized outcome parameters, such as the ASAS Health Index"],"short-title":[],"issued":{"date-parts":[[2022,7,28]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["1241"],"URL":"https:\/\/doi.org\/10.1007\/s00393-022-01241-1","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,28]]},"assertion":[{"value":"17 June 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"U.\u00a0Kiltz, T.\u00a0Wiatr, D.\u00a0Kiefer, X.\u00a0Baraliakos und J.\u00a0Braun geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}